Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer

Journal of Thoracic Oncology

Volumn 12, Issue 7, 2017, Pages 1061-1070

  Jenkins, Suzanne ^a   Yang, James C H ^b   Ramalingam, Suresh S ^c   Yu, Karen ^d   Patel, Sabina ^a   Weston, Susie ^a   Hodge, Rachel ^a   Cantarini, Mireille ^a   Jänne, Pasi A ^e   Mitsudomi, Tetsuya ^f   Goss, Glenwood D ^g  

^a ASTRAZENECA   (United Kingdom)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c EMORY UNIVERSITY   (United States)

^d ROCHE MOLECULAR SYSTEMS   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

circulating tumor DNA; MiSeq next generation sequencing; osimertinib; Roche cobas EGFR Mutation Test; tumor tissue biopsy

Indexed keywords

CHLOROPLAST DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; OSIMERTINIB; DNA;

ADVANCED CANCER; ARTICLE; CLINICAL DECISION MAKING; COBAS TISSUE TEST; CONTROLLED STUDY; DNA DETERMINATION; EGFR GENE; FALSE NEGATIVE RESULT; FEASIBILITY STUDY; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; TISSUE CHARACTERIZATION; BLOOD; FEMALE; GENETICS; LUNG TUMOR; MALE; MUTATION; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85020927802     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2017.04.003     Document Type: Article

References (36)

1. Novello, S., Barlesi, F., Califano, R., et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27 (2016), v1–v27.
2. NCCN Clinical Practice Guidelines in Oncology. Non–small cell lung cancer, Version 5. 2017. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed April 1, 2017.
3. Maemondo, M., Inoue, A., Kobayashi, K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362 (2010), 2380–2388.
4. Mitsudomi, T., Morita, S., Yatabe, Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11 (2010), 121–128.
5. Wu, Y.L., Zhou, C., Liam, C.K., et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 26 (2015), 1883–1889.
6. Wu, Y.-L., Zhou, C., Hu, C.-P., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15 (2014), 213–222.
7. Mok, T.S., Wu, Y.L., Thongprasert, S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 (2009), 947–957.
8. Rosell, R., Carcereny, E., Gervais, R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13 (2012), 239–246.
9. Sequist, L.V., Yang, J.C., Yamamoto, N., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31 (2013), 3327–3334.
10. Xu, M., Xie, Y., Ni, S., Liu, H., The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Ann Transl Med, 3, 2015, 96.
11. Oxnard, G.R., Arcila, M.E., Sima, C.S., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17 (2011), 1616–1622.
12. Yu, H.A., Arcila, M.E., Rekhtman, N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19 (2013), 2240–2247.
13. Overman, M.J., Modak, J., Kopetz, S., et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. J Clin Oncol 31 (2013), 17–22.
14. Thress, K.S., Brant, R., Carr, T.H., et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90 (2015), 509–515.
15. Douillard, J.Y., Ostoros, G., Cobo, M., et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 9 (2014), 1345–1353.
16. Punnoose, E.A., Atwal, S., Liu, W., et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 18 (2012), 2391–2401.
17. Qiu, M., Wang, J., Xu, Y., et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 24 (2015), 206–212.
18. Schwarzenbach, H., Hoon, D.S., Pantel, K., Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11 (2011), 426–437.
19. Aung, K.L., Board, R.E., Ellison, G., et al. Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J 4 (2010), 11–21.
20. Cross, D.A., Ashton, S.E., Ghiorghiu, S., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4 (2014), 1046–1061.
21. Yang, J.C., Ahn, M.J., Kim, D.W., et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol 12 (2017), 1288–1296.
22. Goss, G., Tsai, C.-M., Shepherd, F.A., et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 17 (2016), 1643–1652.
23. Chin, E.L., da Silva, C., Hegde, M., Assessment of clinical analytical sensitivity and specificity of next-generation sequencing for detection of simple and complex mutations. BMC Genet, 14, 2013, 6.
24. U.S. Food and Drug Administration. FDA summary of safety and effectiveness data (SSED). Premarket approval (PMA) P120019, cobas EGFR Mutation Test v2. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019S007. Accessed July 8, 2016.
25. Karlovich, C., Goldman, J.W., Sun, J.M., et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). Clin Cancer Res 22 (2016), 2386–2395.
26. Sacher, A.G., Paweletz, C., Dahlberg, S.E., et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2 (2016), 1014–1022.
27. Oxnard, G.R., Thress, K.S., Alden, R.S., et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 34 (2016), 3375–3382.
28. Sundaresan, T.K., Sequist, L.V., Heymach, J.V., et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res 22 (2016), 1103–1110.
29. Wakelee, H.A., Gadgeel, S.M., Goldman, J.W., et al. Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. [abstract] J Clin Oncol, 34(suppl), 2016, 9001.
30. Chouaid, C., Dujon, C., Do, P., et al. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer 86 (2014), 170–173.
31. Diaz, L.A. Jr., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32 (2014), 579–586.
32. Yoon, H.J., Lee, H.Y., Lee, K.S., et al. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology 265 (2012), 939–948.
33. Agarwal, A., Ressler, D., Snyder, G., The current and future state of companion diagnostics. Pharmacogenomics Pers Med 8 (2015), 99–110.
34. Normanno, N., Denis, M.G., Thress, K.S., Ratcliffe, M., Reck, M., Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget 8 (2016), 12501–12516.
35. Zhu, G., Ye, X., Dong, Z., et al. Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer. J Mol Diagn 17 (2015), 265–272.
36. Yung, T.K., Chan, K.C., Mok, T.S., Tong, J., To, K.F., Lo, Y.M., Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15 (2009), 2076–2084.